Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of understanding and complying with protocol requirements.~2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~3. Has a historical diagnosis of Type 2 diabetes mellitus (T2DM).~4. Male or female and aged 18 to 75 years, inclusive.~5. Body mass index (BMI) between 20 and 45 kg/m\^2, inclusive.~6. A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.~7. Is experiencing inadequate glycemic control defined as glycosylated hemoglobin (HbA1c) concentration between 7.5% and 10%, inclusive, and has been treated with diet and exercise for at least 2 months prior to Screening. (Exception: a participant who has received any other diabetic therapy for less than 7 days in total within the 2 months prior to the screening, can be included).~8. If male, has a hemoglobin \>12 g/dL (\>120 g/L) at Screening or if female, has a hemoglobin \>10 g/dL (\>100 g/L) at Screening.~9. If male, has a serum creatinine \<1.5 mg/dL at Screening or if female, has a serum creatinine \<1.4 mg/dL at Screening, and estimated glomerular filtration rate (eGFR) \>60 mL/min/1.73 m\^2 based on calculation using the Modification of Diet in Renal Disease (MDRD) at Screening.~10. Willing and able to monitor their own blood glucose concentrations using a home glucose monitor and complete a subject diary.~Exclusion Criteria:~1. Participated in another clinical study within 90 days prior to Screening.~2. Received any investigational compound within 30 days prior to Randomization.~3. Received a dipeptidyl peptidase-4 (DPP-4) inhibitor within 3 months prior to screening.~4. History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.~5. History of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.~6. History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.~7. Chronic pancreatitis and/or history of acute pancreatitis.~8. Systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg at Screening.~9. History of any hemoglobinopathy or diagnosis of chronic anemia.~10. New York Heart Association Class III or IV heart failure. (Participants who are stable at Class I or II and are currently treated, are candidates for the study.)~11. History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.~12. History of any cancer, other than squamous cell or basal cell carcinoma of the skin, which has not been in full remission for at least 5 years prior to Screening. Participants with a history of treated cervical intraepithelial neoplasia \[CIN\] I or CIN II are allowed.~13. Significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, human immunodeficiency virus or alanine aminotransferase (ALT) is 2.5 times above upper limit of normal value.~14. History of angioedema in association with use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).~15. History of hypersensitivity or allergies to any DPP-4 inhibitor and/or metformin or related compounds.~16. Has used oral or systemically injected glucocorticoids (including intra-articular injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled or topical corticosteroids were allowed.)~17. History of alcohol or substance abuse within 2 years prior to Screening.~18. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs).~19. History of organ transplantation.~20. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.~21. Has, in the judgment of the investigator, any major illness or debility that may prohibit the participant from completing the study.~22. If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin HCl 500 mg (Type: ACTIVE_COMPARATOR): Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
- Alogliptin 12.5 mg (Type: ACTIVE_COMPARATOR): Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
- Alogliptin 12.5 mg + Metformin HCl 500 mg FDC (Type: EXPERIMENTAL): Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).